Urinary Tract Infections Clinical Trial
Official title:
Characteristics of Hospital- and Community-acquired Urinary Tract Infections Caused by ESBL-producing Enterobacteria in a Tertiary-care Hospital
The aim of this study was to compare the etiologic agents, the antimicrobial resistance rates, and the risk factors associated with a HA-UTI and CA-UTI among complicated and uncomplicated UTI patients in a tertiary-care hospital in Mexico. This study was performed according to the principles expressed in the Declaration of Helsinki with the approval of the Local Ethics Committee of the School of Medicine of the Universidad Autónoma de Nuevo León (UR14-004). All patients with a UTI and a positive urine culture (> 100,000 UFC/mL) from March to October 2015 were included. The study was carried out at the Hospital Universitario "Dr. José Eleuterio González" hospital, a tertiary-care teaching hospital in Monterrey, Mexico. Identification and susceptibility antibiotic assays were performed to all isolates from positive urine culture.
The aim of this study was to compare the etiologic agents, the antimicrobial resistance
rates, and the risk factors associated with a HA-UTI and CA-UTI among complicated and
uncomplicated UTI patients in a tertiary-care hospital in Mexico.
This study was performed according to the principles expressed in the Declaration of Helsinki
with the approval of the Local Ethics Committee of the School of Medicine of the Universidad
Autónoma de Nuevo León (UR14-004).
All patients with a UTI and a positive urine culture (> 100,000 UFC/mL) from March to October
2015 were included. The study was carried out at the Hospital Universitario "Dr. José
Eleuterio González" hospital, a tertiary-care teaching hospital in Monterrey, Mexico. This
hospital has 500 beds, serves a population of approximately 5 million people, and has an
average of 250,000 medical consultations and 22,000 hospitalizations annually.
A UTI was defined as the presence of symptoms related to the urinary tract, pyuria (≥10
leucocytes per high-power field) and a positive urine culture (≥105 CFU/mL) of one
uropathogen according to the guidelines of the Infectious Diseases Society of America (IDSA)
and the European Association of Urology (EAU). Patients with urine cultures with
significative counts of two or more bacterial species were excluded.
Patients' charts were reviewed for clinical and demographic characteristics. The
classification of UTIs as either complicated or uncomplicated, and hospital-acquired or
community-acquired, was based on the IDSA and EAU criteria. Cases which could not be
classified due to insufficient clinical information were excluded.
Urine cultures were performed according to standard protocols. Species identification of all
isolates was performed using MALDI-TOF mass spectrometry (Microflex, Bruker Daltonics,
Billerica, MA). The drug resistance profile of all E. coli isolates was determined using the
broth microdilution method for gentamicin, amoxicillin-clavulanic acid, aztreonam,
ceftriaxone, ertapenem, ciprofloxacin, levofloxacin, nitrofurantoin,
trimethoprim/sulfamethoxazole, and colistin; except fosfomycin, in which the agar dilution
method was used. The results were interpreted according to the Clinical and Laboratory
Standards Institute (CLSI) criteria.
Multidrug resistance (MDR) was defined as non-susceptibility to at least one agent in three
or more antimicrobial categories. All isolates with resistance to at least one
third-generation cephalosporin were evaluated for production of ESBL in E. coli using the
double-disc test according to the CLSI.
Categorical variables were expressed as frequencies and percentages. Numerical variables were
expressed as a mean and standard deviation. Clinical and demographic characteristics were
analyzed using the χ2 test for categorical variables and the t-test (or Mann-Whitney test in
the absence of normal distribution) for continuous variables. Statistical significance was
set at p <0.05. Statistical analysis was performed with the SPSS software version 20.0 (IBM
Corp, Armonk, NY).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04495699 -
Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
|
||
Terminated |
NCT05254808 -
EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care
|
Phase 3 | |
Completed |
NCT03680612 -
Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI
|
Phase 2 | |
Completed |
NCT03282006 -
Treating Pyelonephritis an Urosepsis With Pivmecillinam
|
Phase 4 | |
Completed |
NCT03526484 -
The Utility of Urinalysis Prior to In-Office Procedures
|
N/A | |
Completed |
NCT05397782 -
Effects of Flourish on Recurrent Urinary Tract Infection
|
N/A | |
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03687255 -
Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections
|
Phase 3 | |
Recruiting |
NCT05227937 -
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
|
||
Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
Completed |
NCT03131609 -
Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
|
||
Completed |
NCT01911143 -
A Retrospective, Blinded Validation of a Host-response Based Diagnostics
|
N/A | |
Completed |
NCT01333254 -
A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients
|
N/A | |
Terminated |
NCT00594594 -
Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury
|
Phase 1 | |
Completed |
NCT00216853 -
A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection
|
N/A | |
Completed |
NCT00787085 -
The Significance of Funguria in Hospitalized Patients
|
N/A | |
Completed |
NCT05719753 -
The Effectiveness of a Bacteriophobic Coating on Urinary Catheters
|
N/A | |
Recruiting |
NCT05415865 -
The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder
|
Phase 3 | |
Not yet recruiting |
NCT05880329 -
DIagnoSing Care hOme UTI Study
|
||
Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|